Whitehawk Therapeutics to Participate in H.C. Wainwright "HCW@Home" Series

On June 19, 2025 Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, reported that Dave Lennon, PhD, President and CEO, and David Dornan, PhD, Chief Scientific Officer, will participate in the virtual H.C. Wainwright "HCW@Home" series on Thursday, June 26, 2025, at 10 AM ET (Press release, Whitehawk Therapeutics, JUN 19, 2025, View Source [SID1234654008]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To register in advance, please use this link. A live webcast of the event can be accessed by visiting the "Investors & News" page on the Whitehawk Therapeutics website and will be available for replay for approximately 30 days following the event.